622 results about "D-GLUCURONIC ACID" patented technology

This invention provides methods and devices for spatially separating at least first and second components in a sample which in one exemplary embodiment comprises introducing the first and second components into a first microfluidic channel of a microfluidic device in a carrier fluid comprising a spacer electrolyte solution and stacking the first and second components by isotachophoresis between a leading electrolyte solution and a trailing electrolyte solution, wherein the spacer electrolyte solution comprises ions which have an intermediate mobility in an electric field between the mobility of the ions present in the leading and trailing electrolyte solutions and wherein the spacer electrolyte solution comprises at least one of the following spacer ions MOPS, MES, Nonanoic acid, D-Glucuronic acid, Acetylsalicyclic acid, 4-Ethoxybenzoic acid, Glutaric acid, 3-Phenylpropionic acid, Phenoxyacetic acid, Cysteine, hippuric acid, p-hydroxyphenylacetic acid, isopropylmalonic acid, itaconic acid, citraconic acid, 3,5-dimethylbenzoic acid, 2,3-dimethylbenzoic acid, p-hydroxycinnamic acid, and 5-br-2,4-dihydroxybenzoic acid, and wherein the first component comprises a DNA-antibody conjugate and the second component comprises a complex of the DNA-antibody conjugate and an analyte.

Novel estrogenic compounds of Formula I are provided.

wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R₁ is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R₁ does not exist; R₂ is lower alkyl; R₃ may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R₄ through R₁₃ may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R₁₄ is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R₁ is hydroxy, the hydroxy or ester substituent may have either an α or a β orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.

The invention provides a method of modifying soluble xylan which contains glucuronic acid and/or arabinose side chains so that it can be adsorbed onto other substrates. The method includes the steps of enzymatically modifying the xylan by selectively removing glucuronic acid and/or arabinose side chains from the xylan with α-D-glucuronidase and/or α-L-arabinofuranosidase, and allowing the modified xylan to adsorb onto the substrate. The substrate may be a cellulosic substrate like pulp or paper or a non-cellulosic substrate. The enzymes are able to remove a sufficient number of the xylan side chains so as to decrease water solubility of the xylan, induce xylan precipitation and allow adsorption of the xylan onto other substrates. A pulping process which incorporates modification of xylan and adsorption onto cellulosic material is also provided, as are products which contain the modified xylan.

The invention relates to a resveratrol and bioflavonoid nutritional composition for delaying senility or used for treating and preventing diseases relevant to aging. The invention adopts the combination of resveratrol and bioflavonoid and prepares oral liquid, capsules, tablets, granules and powder. The invention overcomes the defect that the absorptivity of antitype resveratrol in the prior art is very high, but the bioavailability is very low; A composition of the resveratrol and quercetin can prolong the detention time of the resveratrol in blood and enhance the acting time of the resveratrol, but only part of the resveratrol is not metabolized and acts together with the quercetin to enhance the function of delaying senility; and the rest part of the resveratrol after being converted into the sulfate or glucuronic acid salt of the resveratrol by metabolism does not generate a synergistic action with the quercetin again, and the effect of the resveratrol for delaying senility is lowered. The invention greatly prolongs the detention time of the resveratrol in a human body, exerts the function of the resveratrol for resisting senility, solves the problem that the resveratrol is metabolized, and is innoxious.

The present invention provides a preparation method, antivirus applications and the like of a forsythoside glucuronic acid derivative represented by the following formula, wherein R is H, Me, Na<+>, K<+>, and the like.

The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction rate of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction rate as that of the conventionally known gel.

The invention belongs to the field of marine medicines, and relates to a fucosan sulphate, a preparation method thereof and application of the fucosan sulphate in preparing an anti-influenza virus medicine. Polysaccharide with a main chain taking alpha-1,2-D-mannose and beta-1,4-D-glucuronic acid as repetitive units, and with a branched chain of alpha-1,3-L-fucosan sulphate is obtained by virtue of hot-water extraction, calcium chloride precipitation and DEAE-Cellulose chromatographic column purification. The fucosan sulphate prepared by the invention is high in inhibition effect on the influenza virus neuraminidase activities of A H1N1, H5N1 and H3N2, and obvious in protection effect on the dog kidney epithelial cells infected by A H1N1. The fucosan sulphate provided by the invention has the advantages of being rich in raw material source, simple in preparation process, easy to industrialize, high in product water solubility, high in stability, free from toxic and side effects, and the like, and has the prospect of being developed to the anti-influenza virus medicine.

The invention discloses a carboxylic ester of fucosylated glycosaminoglycan (CEFG) with anticoagulation activity, a pharmaceutically acceptable salt thereof, a preparation method of the CEFG and the pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the CEFG or the salt thereof, and application of the pharmaceutical composition in preparation of anticoagulants. The monosaccharides for preparing the CEFG comprise D-glucuronic acid or D-glucuronate (D-GlcU), D-2-deoxy-2-acetyl galactosamine sulfate (D-GalNAcS) and L-fucose sulfate (L-FucS), wherein the molar ratio of D-GlcU to D-GalNAc to L-Fuc to -OSO3<-> is 1:(1+/-0.3):(1+/-0.3):(3.5+/-0.5); the esterification degree of the D-GlcU is not lower than 20%; and the weight average molecular weight of the CEFG is 3000-20000 Da. The glycosylated chondroitin sulfate esterification derivative has strong anticoagulation activity, and can be applied in preparation of drugs for preventing and/or treating thrombotic diseases.

A method for producing a chondroitin sugar chain comprises at least the following step: a step of allowing “a glucuronic acid donor”, “an N-acetyl galactosamine donor”, “a sugar receptor” and “a bacterial cell enzyme which synthesizes chondroitin” to coexist in a reaction system in the presence of a surfactant. Here, the surfactant is preferably selected from n-nonyl-β-D-thiomaltopyranoside, sucrose monocaproate and sucrose monolaurate. The chondroitin sugar chain has all the following properties 1) to 3): 1) a weight average molecular weight: 50,000 or more when it is measured by gel filtration chromatography, 2) it is completely degraded to disaccharides with chondroitinase ABC, 3) when the sugar chain is decomposed with chondroitinase ABC and the decomposed products are subjected to a disaccharide analysis, substantially all of them correspond to an unsaturated disaccharide unit of chondroitin.

The invention discloses low molecular weight carboxyl-reduced derivatives of fucosylated glycosaminoglycans (LCRG). The extent of carboxyl reduction is not less than 20%. Weight-average molecular weight of the LCRG is about 3000-20000Da, and monosaccharides comprise acetyl galactosamine (GalNAc), glucose (Glc) or glucuronic acid (GlcUA) and fucose (Fuc) or sulfates of fucose (shown as -OSO3-). The mole ratio of GalNAc, Glc (containing GlcUA), Fuc and -OSO3- is about 1: (1+-0.3): (1+-0.3): (3.0+-1.0). The LCRG is a potent human immunodeficiency virus (HIV) Type 1 entry inhibitor which acts on conserved regions and has the advantages of high activity against HIV Type 1, high therapeutic index and no-drug-resistance, and the LCRG can be used for preventing or curing HIV. The invention further provides a preparation method of the LCRG. The carboxyl-reduced derivatives of fucosylated glycosaminoglycans and medicinal compositions of the carboxyl-reduced derivatives can be prepared into injection agents, lyophilized powder or suppository and the like.

A human-derived novel chondroitin synthase, which is an enzyme for synthesizing a fundamental backbone of chondroitin and has both glucuronic acid transferase activity and N-acetylgalactosamine transferase activity.

The invention discloses a method for preparing a hemicellulose/nano-silver colloid rapidly. The method includes the steps that in a water phase, hemicellulose and silver ammonia solution are subjected to a redox reaction under the microwave condition to generate nano-silver particles; the hemicellulose is extracted from the grass family, the weight-average molecular weight of the hemicellulose is 4.5*104 g/mol-5.5*104 g/mol, and the hemicellulose comprises, by mass percent, the following carbohydrate components: 85-90% of wood sugar, 7.5-12% of arabinose, 0.5-1% of glucose, 0.15-0.65% of galactose, 0.08-0.15% of mannose and 1.05-2.95% of glucuronic acid. The preparation meets the requirement for green chemistry, and the method is a nano-metal preparing method which is green and rapid to implement. A new conception is provided for the green synthesis of nano-silver, the hemicellulose resource is reasonably utilized, and the nano-silver colloid has application prospects in the biological field and the medical field.

The invention discloses a Ziyang selenium-rich green tea selenium-containing polysaccharide, which comprises the following components in percentage by mass: 1.5-8.5 ppm selenium and the balance of heterosaccharide. The heterosaccharide comprises the following components in percentage by mol: 3.3-5.3% of mannitose, 1-2% of ribose, 3.5-5% of rhamnose, 2-3.5% of glucuronic acid, 2.6-3.8% of galacturonic acid, 30-34.2% of glucose, 3.6-5.6% of xylose, 19.8-23.2% of galactose and 21.5-25.6% of arabinose. The invention also provides a preparation method and application of the Ziyang selenium-rich green tea selenium-containing polysaccharide. The preparation method is simple and convenient, has the advantage of low cost, and is suitable for popularization; and the selenium-containing polysaccharide has the action of enhancing immunity, has obvious inhibiting actions on growth of colon cancer cells, and has obvious protective actions on hepatic injury.

The invention discloses a low molecular weight glycosylated chondroitin sulfate, whose weight average molecular weight is 3000-15000Da. The monosaccharide composition comprises acetyl galactosamine (D-GalNAc), glucuronic acid (D-GlcUA), fucose (L-Fuc), or its sulfuric ester (expressed in -OS03<->), wherein the mole ratio of D-GalNAc to D-GlcUA to L-Fuc to -OS03<-> is 1: (1+/-0.3): (1+/-0.3): (3.5+/-0.5). The low molecular weight glycosylated chondroitin sulfate has a strong anti-HIV-1 virus activity, is a gp120 entry inhibitor, and can be used for preventing and/or treating AIDS. The invention also provides a method for preparing the low molecular weight glycosylated chondroitin sulfate and its composition preparation. Glycosylated chondroitin sulfate is depolymerized by the peroxide method to obtain a low molecular weight product, and then low molecular and/or high-molecular impurities of the product are removed by gel separation or ultrafiltration method. The low molecular weight glycosylated chondroitin sulfate and its medicinal composition can be prepared in the form of an injection, a lyophilized powder or a suppository.

The invention provides a chemical method for preparing 5,6,4'-trihydroxyflavone-7-O-D-glucuronic acid to solve problems of unavailable raw materials, long synthetic route and low synthesis yield in the existing synthetic method. The method comprises a plurality of chemical reaction steps: first, taking 3,4,5-trimethoxy phenol and p-methoxy cinnamoyl chloride as the raw materials to construct a chalcone structure by a Friedel-Crafts acylation reaction, and cycloetherifying to obtain a flavone parent substance; then protecting and selectively deprotecting phenolic hydroxyl of the flavone parent substance, and glycosylating 7-phenolic hydroxyl; and finally removing a protective group to obtain the target compound. The obtained product has a beta-steric configuration. The method can be used for preparing high-purity and high-quality 5,6,4'-trihydroxyflavone-7-O-D-glucuronic acid products.

The invention provides low-molecular-weight fucosylated chondroitin sulfate, a preparation method thereof and application of the low-molecular-weight fucosylated chondroitin sulfate to the preparation of medicine for resisting Trousseau syndrome. Sulfated polysaccharide with the main chain using beta-1,4-D-glucuronic acid and beta-1,3-D-acetamino galactose as disaccharide repeating units and the branch chain being alpha-1,3-L-fucus oligosaccharide sulfate. Experiments show that the fucosylated chondroitin sulfate has an evident inhibiting effect on the Trousseau syndrome. The fucosylated chondroitin sulfate is rich in raw material source, simple in preparation process, easy in industrialization, high in product safety, good in stability, unique in activity, promising in technical prospect in the development of medicine for resisting the Trousseau syndrome, and the like.

The invention discloses a method for testing quality of perfoliate knotweed medicinal material, which includes part or whole of description, identification, examination and content measurement. The aforementioned identification includes thin-layered chromatography of taking quercetin reference substance and/or quercetin-3-O-beta-D-n butyl glucuronic acid reference substance as contrast, the content measurement measures the content of quercetin in medicinal materials, which is indicated as a high performance liquid chromatography of taking quercetin as contrast and the organic facies : aqueous phase as 10-40 : 90-60. Compared to the existing technology, the invention perfects the quality detecting standard of perfoliate knotweed medicinal materials, recuperates the deficiency of the existing quality detecting technology, which makes this quality detecting technology more scientific and reasonable, and ensures its security and validity in clinical application.

Disclosed are conjugates comprising a central nervous system-active drug linked through an amide bond to a glucuronic acid or glucosamine moiety, and uses thereof, e.g., for treating or ameliorating central nervous system diseases or disorders.

The invention belongs to the field of energy technology and food technology, and more particularly relates to a polymer and the application thereof. The polymer is composed of 34.8% of sugar, 63.1% of fat and 1.5% of polypeptide; wherein, the sugar component contains glucose, rhamnose, seminose and glucuronic acid; fat component contains 6.2% of hexadecanoic acid methyl ester and 93.8% of methyl stearate; the polypeptide component respectively contains 11.6% of asparticacid, 6.1% of threonine, 4.8% of serine, 11.7% of glutamic acid, 6.7% of glycin, 9.8% of lactamine, 6.7% of valine, 1.8% of methionine , 4.6% of isoleucine, 9.8% of leucine, 3.4% of tyrosine, 5.9% of phenyl alanine, 3.1% of lysine, 1.3% of histidine, 7.6% of arginine and 5.2% of proline. Sanzanjiao can be taken as drilling mud conditioner and jelly glue polymer used for water shutoff profile control treatment in oil field to be applied to petroleum extraction, and the characteristics of jelling and thickening lead the polymer to be taken as food additive to be widely applied to the food production field.

The invention relates to glucose-rich spirulina polysaccharide and an application thereof in a plant green pesticide and an anti-tumor drug. High-sugar spirulina obtained through nutritional regulation is used as a raw material and is subjected to hot water extraction, protein removal with a flocculant, concentration, precipitation and freeze drying to obtain the water-soluble high-sugar spirulina polysaccharide having the molecular weight of 10-200 kDa; the spirulina polysaccharide comprises the monosaccharides mainly comprising rhamnose, fucose, arabinose, xylose, mannose, galactose, glucose, glucuronic acid and galacturonic acid, and is characterized in that the glucose content is more than 50% in the monosaccharide composition. The spirulina polysaccharide can obviously induce plant disease resistance, has obvious anti-tumor effect on tumor, and can be used as the biological pesticide and the anti-tumor drug.

Heparin is synthesized from a polysaccharide comprised of a 1-4 glycosidically linked alternating polymer of uronic acid and glucosamine residues, wherein the uronic acid is selected from iduronic and glucuronic acid, wherein the glucosamine is partially N-sulfated; by a series of selective reactions catalyzed by recombinant enzymes.

A human-derived novel chondroitin synthase, which is an enzyme for synthesizing a fundamental backbone of chondroitin and has both glucuronic acid transferring activity and N-acetylgalactosamine transferring activity.

A biodegradable hyaluronic acid derivative comprising a modified hyaluronic acid repeating unit represented by the formula (HA)-[O(C═O)NH-M]_p, wherein HA is a unit including N-acetyl-D-glucosamine and D-glucuronic acid, M is a modifying moiety containing a C_2-16 hydrocarbyl group or a prepolymer, and p is an integer of 1 to 4. The biodegradable hyaluronic acid derivative when dissolved in a hydrophilic medium can form micelles and can be used to entrap a pharmaceutically active or bioactive molecule.